There is no biologic of choice for patients with Myasthenia Gravis (MG). Given the disease's rarity, the data is scant. A prospective pilot trial of etanercept in 11 patients with corticosteroid-dependent observed that 6 of the 8 patients who completed the trial improved, based on quantitative measu...